Aditxt, Inc. Finance Lease, Right-of-Use Asset, Amortization
Aditxt, Inc. (ADTX) reported Finance Lease, Right-of-Use Asset, Amortization of $2.20 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2024-04-16
- Aditxt, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2023-12-31 was -$254.59K.
- Aditxt, Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $2.20M, a 30.38% decline from fiscal 2022.
- Aditxt, Inc. finance lease, right-of-use asset, amortization for fiscal 2022 was $3.16M.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|
| 2023-12-31 | -$254.59K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $2.20M 10-K · filed 2024-04-16 | |
| 2023-09-30 | $2.45M 10-Q · filed 2023-11-14 | ||
| 2022-12-31 | $3.16M 10-Q · filed 2023-11-14 | $3.16M 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |